Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test
← catalyst calendarSponsored by CareDx (industry) · CDNA — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
307actual
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-06-30 | actual | When the study began enrolling |
| Primary completion | 2026-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-11-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndrome
Primary outcome
what the primary-completion date above is the date OFTo determine the association between increased mixed chimerism (iMC) detected by AlloHeme and post-transplant relapse in patients with acute leukemia and myelodysplastic syndrome.
measured Jan-2022
Permalink · CDNA's whole pipeline · Catalyst calendar · Every registered study · What changed